Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Other Accumulated Expenses (2020 - 2023)

Historic Other Accumulated Expenses for Sight Sciences (SGHT) over the last 4 years, with Q3 2023 value amounting to $1.5 million.

  • Sight Sciences' Other Accumulated Expenses rose 5671.32% to $1.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.5 million, marking a year-over-year increase of 5671.32%. This contributed to the annual value of $1.1 million for FY2022, which is 6595.42% up from last year.
  • As of Q3 2023, Sight Sciences' Other Accumulated Expenses stood at $1.5 million, which was up 5671.32% from $1.3 million recorded in Q2 2023.
  • In the past 5 years, Sight Sciences' Other Accumulated Expenses registered a high of $1.5 million during Q3 2023, and its lowest value of $446000.0 during Q4 2020.
  • Moreover, its 4-year median value for Other Accumulated Expenses was $839000.0 (2022), whereas its average is $843636.4.
  • Per our database at Business Quant, Sight Sciences' Other Accumulated Expenses skyrocketed by 8399.12% in 2022 and then skyrocketed by 2037.79% in 2023.
  • Quarter analysis of 4 years shows Sight Sciences' Other Accumulated Expenses stood at $446000.0 in 2020, then surged by 46.86% to $655000.0 in 2021, then surged by 65.95% to $1.1 million in 2022, then skyrocketed by 34.22% to $1.5 million in 2023.
  • Its Other Accumulated Expenses stands at $1.5 million for Q3 2023, versus $1.3 million for Q2 2023 and $892000.0 for Q1 2023.